The current study shows the successfulsynthesis of [methylpiperazine-11C]brigatinib,the preclinical evaluation in femalenu/nu mice bearing subcutaneous NSCLC tumors, and the ability of [methylpiperazine-11C]brigatinib to differentiatebetween the EML4–ALK mutation expressing H2228 and the ALKwild-type expressing A549. The gene discussed is ALK; the disease is non-small cell lung carcinoma.